1389 related articles for article (PubMed ID: 29183778)
1. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
2. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
3. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
6. Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.
Sharma R; Wang Y; Chen L; Gurda GT; Geddes S; Gabrielson E; Askin F; Li QK
Hum Pathol; 2016 Aug; 54():8-16. PubMed ID: 27045515
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.
Kayser G; Csanadi A; Otto C; Plönes T; Bittermann N; Rawluk J; Passlick B; Werner M
PLoS One; 2013; 8(2):e56333. PubMed ID: 23418554
[TBL] [Abstract][Full Text] [Related]
8. [New perspectives in the management of non-small-cell lung carcinoma (NSCLC)].
Brockmöller J; Junker K; Multhoff G
Onkologie; 2006 Sep; 29 Suppl 2():25-8. PubMed ID: 16974125
[No Abstract] [Full Text] [Related]
9. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects.
Osmani L; Li QK
Biomark Med; 2017 May; 11(5):405-407. PubMed ID: 28621614
[No Abstract] [Full Text] [Related]
12. Targeted Therapy and Immunotherapy for Lung Cancer.
Naylor EC; Desani JK; Chung PK
Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
Shroff GS; de Groot PM; Papadimitrakopoulou VA; Truong MT; Carter BW
Radiol Clin North Am; 2018 May; 56(3):485-495. PubMed ID: 29622080
[TBL] [Abstract][Full Text] [Related]
14. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.
da Cunha Santos G; Lai SW; Saieg MA; Geddie WR; Pintilie M; Tsao MS; Boerner SL; Hwang D
Lung Cancer; 2012 Sep; 77(3):501-6. PubMed ID: 22656670
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
Guven DC; Sahin TK; Dizdar O; Kilickap S
Biomark Med; 2020 Oct; 14(14):1383-1392. PubMed ID: 33064030
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
[TBL] [Abstract][Full Text] [Related]
18. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
19. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]